Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1993 Dec;37(12):2674–2677. doi: 10.1128/aac.37.12.2674

Influence of local radiotherapy on penetration of fluconazole into human saliva.

J Oliary 1, M Tod 1, K Louchahi 1, O Petitjean 1, B Frachet 1, V Le Gros 1, N Brion 1
PMCID: PMC192775  PMID: 8109935

Abstract

The pharmacokinetics of fluconazole (50 mg, single oral dose) in saliva and plasma were determined for five healthy subjects and five patients who underwent radiotherapy (dose, > 45 Gy over a 6-week period) in the salivary gland area and suffered from oropharyngeal candidiasis. Saliva was collected after electrical stimulation. Fluconazole was measured by liquid chromatography. From healthy volunteers and patients, saliva and plasma were sampled from 0 to 24 h. Although fluconazole penetration kinetics were significantly slowed down in irradiated patients, saliva concentrations of fluconazole were higher than those in the plasma, except at 1 h. In the postdistribution phase, the saliva/plasma concentration ratio was in the range of 1.2 to 1.4, and there was no significant difference between healthy subjects and patients. The saliva concentration of fluconazole was over 1 mg/liter throughout the entire interval 2 to 24 h after drug intake. From these results, the clinical efficacy of fluconazole for oropharyngeal candidiasis is not expected to be less than that in subjects with normal salivary glands, provided that salivary secretion remains.

Full text

PDF
2674

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allen M. A., Wrenn J. M., Putney J. W., Jr, Borzelleca J. F. A study of the mechanism of transport of diphenylhydantoin in the rat submaxillary gland in vitro. J Pharmacol Exp Ther. 1976 May;197(2):408–413. [PubMed] [Google Scholar]
  2. Borzelleca J. F., Cherrick H. M. The excretion of drugs in saliva. Antibiotics. J Oral Ther Pharmacol. 1965 Nov;2(3):180–187. [PubMed] [Google Scholar]
  3. Danhof M., Breimer D. D. Therapeutic drug monitoring in saliva. Clin Pharmacokinet. 1978 Jan-Feb;3(1):39–57. doi: 10.2165/00003088-197803010-00003. [DOI] [PubMed] [Google Scholar]
  4. Davis R. E., Hartman C. W., Fincher J. H. Dialysis of ephedrine and pentobarbital from whole human saliva and simulated saliva. J Pharm Sci. 1971 Mar;60(3):429–432. doi: 10.1002/jps.2600600318. [DOI] [PubMed] [Google Scholar]
  5. De Wit S., Weerts D., Goossens H., Clumeck N. Comparison of fluconazole and ketoconazole for oropharyngeal candidiasis in AIDS. Lancet. 1989 Apr 8;1(8641):746–748. doi: 10.1016/s0140-6736(89)92572-5. [DOI] [PubMed] [Google Scholar]
  6. Dupont B., Drouhet E. Fluconazole in the management of oropharyngeal candidosis in a predominantly HIV antibody-positive group of patients. J Med Vet Mycol. 1988 Feb;26(1):67–71. doi: 10.1080/02681218880000081. [DOI] [PubMed] [Google Scholar]
  7. Fischman A. J., Alpert N. M., Livni E., Ray S., Sinclair I., Callahan R. J., Correia J. A., Webb D., Strauss H. W., Rubin R. H. Pharmacokinetics of 18F-labeled fluconazole in healthy human subjects by positron emission tomography. Antimicrob Agents Chemother. 1993 Jun;37(6):1270–1277. doi: 10.1128/aac.37.6.1270. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Fischman A. J., Alpert N. M., Livni E., Ray S., Sinclair I., Elmaleh D. R., Weiss S., Correia J. A., Webb D., Liss R. Pharmacokinetics of 18F-labeled fluconazole in rabbits with candidal infections studied with positron emission tomography. J Pharmacol Exp Ther. 1991 Dec;259(3):1351–1359. [PubMed] [Google Scholar]
  9. Foulds G., Brennan D. R., Wajszczuk C., Catanzaro A., Garg D. C., Knopf W., Rinaldi M., Weidler D. J. Fluconazole penetration into cerebrospinal fluid in humans. J Clin Pharmacol. 1988 Apr;28(4):363–366. doi: 10.1002/j.1552-4604.1988.tb03159.x. [DOI] [PubMed] [Google Scholar]
  10. Groth U., Prellwitz W., Jähnchen E. Estimation of pharmacokinetic parameters of lithium from saliva and urine. Clin Pharmacol Ther. 1974 Sep;16(3):490–498. doi: 10.1002/cpt1974163part1490. [DOI] [PubMed] [Google Scholar]
  11. Iwamoto K., Watanabe J., Kanai Y., Mizuno S., Ozeki S. Effect of perfused rat mandibular-gland pHI on the ratio of procainamide concentration in saliva to that in venous effluent. Biochem Pharmacol. 1988 Apr 15;37(8):1519–1523. doi: 10.1016/0006-2952(88)90013-5. [DOI] [PubMed] [Google Scholar]
  12. Konzelman J. L., Jr Oral implications of radiotherapy and chemotherapy. J Oral Med. 1983 Apr-Jun;38(2):76–78. [PubMed] [Google Scholar]
  13. Lange W. E., Floriddia D. G., Pruyn F. J. In vitro binding of salicylates to saliva proteins. J Pharm Sci. 1969 Jun;58(6):771–773. doi: 10.1002/jps.2600580632. [DOI] [PubMed] [Google Scholar]
  14. Matin S. B., Wan S. H., Karam J. H. Pharmacokinetics of tolbutamide: prediction by concentration in saliva. Clin Pharmacol Ther. 1974 Dec;16(6):1052–1058. doi: 10.1002/cpt19741661052. [DOI] [PubMed] [Google Scholar]
  15. Ogubona F. A., Lawal A. A., Onyeji C. O. Saliva secretion of chloroquine in man. J Pharm Pharmacol. 1986 Jul;38(7):535–537. doi: 10.1111/j.2042-7158.1986.tb04632.x. [DOI] [PubMed] [Google Scholar]
  16. Patey O., Breuil J., Fisch A., Burnat C., Vincent-Ballereau F., DuBlanchet A. Bacteroides fragilis meningitis: report of two cases. Rev Infect Dis. 1990 Mar-Apr;12(2):364–365. doi: 10.1093/clinids/12.2.364. [DOI] [PubMed] [Google Scholar]
  17. Posti J. Saliva-plasma drug concentration ratios during absorption: theoretical considerations and pharmacokinetic implications. Pharm Acta Helv. 1982;57(3):83–92. [PubMed] [Google Scholar]
  18. Rossie K. M., Taylor J., Beck F. M., Hodgson S. E., Blozis G. G. Influence of radiation therapy on oral Candida albicans colonization: a quantitative assessment. Oral Surg Oral Med Oral Pathol. 1987 Dec;64(6):698–701. doi: 10.1016/0030-4220(87)90171-x. [DOI] [PubMed] [Google Scholar]
  19. Savani D. V., Perfect J. R., Cobo L. M., Durack D. T. Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis. Antimicrob Agents Chemother. 1987 Jan;31(1):6–10. doi: 10.1128/aac.31.1.6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Schubert M. M., Izutsu K. T. Iatrogenic causes of salivary gland dysfunction. J Dent Res. 1987 Feb;66(Spec No):680–688. doi: 10.1177/00220345870660S213. [DOI] [PubMed] [Google Scholar]
  21. Vital Durand D., Piolat C., Soucheleau J., Baltassat P., Brazier J. L. Pharmacocinétique de l'antipyrine. Comparaison des concentrations totales, libres et salivaires. Therapie. 1988 Jun-Jul;43(4):263–266. [PubMed] [Google Scholar]
  22. Zuidema J., van Ginneken C. A. Clearance concept in salivary drug excretion. Part I: theory. Pharm Acta Helv. 1983;58(3):88–93. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES